

COMBINATION THERAPY FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS

[Amin, Neha](#), [Borcherding, Dana](#), [Hirbe, Angela](#)

[Hanford, Charles](#)

T-020000

Technology Description

Researchers in Angela Hirbe's lab at Washington University have developed a method of treating malignant peripheral nerve sheath tumors (MPNSTs) with a combination of inhibitors. The most effective therapy is to combine an inhibitor of TYK2 with a MEK inhibitor.

MPNSTs are often associated with Neurofibromatosis Type 1 or as a secondary complication of radiation therapy. Despite multiple therapeutic options, 50% of patients see a recurrence.

Stage of Research

The researchers have tested the combination of TYK2 and MEK inhibitors on MPNST cells *in vitro* and on an NF1 model *in vivo*.

Applications

- Malignant peripheral nerve sheath tumors (MPNSTs)

Key Advantages

- Increases response to MEK inhibitor

Patents: Pending

Related Web Links: Hirbe [Profile](#) & [Lab](#)